LGT Group Foundation Acquires 4,335 Shares of Zoetis Inc. (NYSE:ZTS)

LGT Group Foundation lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 46,747 shares of the company’s stock after purchasing an additional 4,335 shares during the period. LGT Group Foundation’s holdings in Zoetis were worth $8,104,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ZTS. Vanguard Group Inc. boosted its holdings in Zoetis by 1.0% in the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after acquiring an additional 414,605 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after acquiring an additional 3,244,074 shares during the last quarter. Capital World Investors boosted its holdings in Zoetis by 0.6% in the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock valued at $1,788,988,000 after acquiring an additional 57,798 shares during the last quarter. Norges Bank bought a new position in Zoetis in the fourth quarter valued at about $980,646,000. Finally, Bank of New York Mellon Corp boosted its holdings in Zoetis by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after acquiring an additional 178,303 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.2 %

ZTS stock traded up $2.36 during mid-day trading on Monday, reaching $191.59. The company had a trading volume of 304,538 shares, compared to its average volume of 2,647,988. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The stock has a 50 day simple moving average of $181.22 and a two-hundred day simple moving average of $174.39. The company has a market capitalization of $87.42 billion, a price-to-earnings ratio of 36.46, a PEG ratio of 2.90 and a beta of 0.88. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.41 earnings per share. As a group, equities analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent analyst reports. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 price target on shares of Zoetis in a research report on Tuesday, August 27th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.